3-(2,4-dimethoxybenzylidene)anabaseine has been researched along with Idiopathic Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, JL; Kim, DY; Kim, HS; Leem, YH; Park, JE; Park, JS | 1 |
| Hisahara, S; Kawamata, J; Kem, W; Kitamura, Y; Matsumura, A; Matsushita, T; Shimohama, S; Suzuki, S; Takata, K | 1 |
2 other study(ies) available for 3-(2,4-dimethoxybenzylidene)anabaseine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Benzylidene Compounds; Disease Models, Animal; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Microglia; Neurodegenerative Diseases; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappa B; Nicotinic Agonists; Parkinson Disease; Phosphatidylinositol 3-Kinases; Pyridines | 2022 |
3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzylidene Compounds; Female; Neurodegenerative Diseases; Neuroprotective Agents; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic | 2013 |